Biomarker discovery for drug development and translational medicine using metabonomics.
There exists at present an urgent desire for better biomarkers, especially in the context of pharmaceutical drug development and in the detection and management of disease. Many researchers in the area of biomarker discovery and development have turned to the "-omics" sciences as a way of addressing these needs. Metabolic profiling, or metabonomics, defines the metabolic phenotype and offers a source of novel biomarkers that have better potential to translate effectively. This review will discuss the broad philosophy and motivations behind metabonomics, and illustrate the case with applications relevant to pharmaceutical development and patient management. Particular focus will be paid to the potential of metabonomics to contribute to biomarker discovery in toxicology and cancer research.
Keun
H C
HC
Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College Faculty of Medicine, Sir Alexander Fleming Building, Exhibition Road, SW7 2AZ South Kensington, London, UK. h.keun@imperial.ac.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D015415:Biomarkers; D015195:Drug Design; D006801:Humans; D008660:Metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D014116:Toxicology
D000970:Antineoplastic Agents; D015415:Biomarkers